TransMedics Group, Inc. (TMDX) Stock
Key stats
- Market cap
- $3.20B
- Price / Earnings ratio
- 21.9x
- EPS (TTM)
- $4.22
- Volume
- Loading
- 52-week high
- $156.00
- 52-week low
- $60.11
Source: third-party data provider, as of November 13, 2026
Compare with TMDX
Recent news
TMDX Investors Have Opportunity to Join TransMedics Group, Inc. Fraud Investigation with SBS Law
TMDX Investors Have Opportunity to Join TransMedics Group, Inc. Fraud Investigation with SBS Law
TMDX
2 Stocks Down 28% and 34% to Buy and Hold
2 Stocks Down 28% and 34% to Buy and Hold
TMDX
TransMedics Group Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of TransMedics Group, Inc. - TMDX
TransMedics Group Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of TransMedics Group, Inc. - TMDX
TMDX
Is TMDX Stock Worth Buying as Growth Meets Rising Margin Pressure?
Is TMDX Stock Worth Buying as Growth Meets Rising Margin Pressure?
TMDXNews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 67.00
- MACD 12/26/9
- 2.34
- EMA 9 of MACD
- -0.94
- MACD histogram
- 3.28
- SMA 50
- $80.04
- Price above SMA 50
- EMA 50
- $78.92
- Price above EMA 50
- SMA 200
- $92.11
- Price below SMA 200
- EMA 200
- $95.03
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 6 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $0.57 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news
TMDX Investors Have Opportunity to Join TransMedics Group, Inc. Fraud Investigation with SBS Law
TMDX Investors Have Opportunity to Join TransMedics Group, Inc. Fraud Investigation with SBS Law
TMDX2 Stocks Down 28% and 34% to Buy and Hold
2 Stocks Down 28% and 34% to Buy and Hold
TMDXTransMedics Group Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of TransMedics Group, Inc. - TMDX
TransMedics Group Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of TransMedics Group, Inc. - TMDX
TMDXIs TMDX Stock Worth Buying as Growth Meets Rising Margin Pressure?
Is TMDX Stock Worth Buying as Growth Meets Rising Margin Pressure?
TMDX
Why Is TransMedics (TMDX) Up 10.2% Since Last Earnings Report?
Why Is TransMedics (TMDX) Up 10.2% Since Last Earnings Report?
TMDX
TransMedics Targets $2B Opportunity With Kidney Push, European Expansion
TransMedics Targets $2B Opportunity With Kidney Push, European Expansion
TMDX
TransMedics Group Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of TransMedics Group, Inc. - TMDX
TransMedics Group Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of TransMedics Group, Inc. - TMDX
TMDX
TransMedics Stock Dips Post Q2 Earnings Miss, Margins Contract
TransMedics Stock Dips Post Q2 Earnings Miss, Margins Contract
TMDX
Why TransMedics Stock Is Sinking Today
Why TransMedics Stock Is Sinking Today
TMDX
TransMedics Group Q2 Earnings Call Highlights
TransMedics Group Q2 Earnings Call Highlights
TMDXNews tone: automated (AI) classification of the article's content, not a price prediction.
About TransMedics Group, Inc.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Waleed H. Hassanein M.D. | Founder, President, CEO & Director | 1968 |
| Mr. Anil Ranganath | Advisor | 1982 |
| Mr. Matthew Forsyth | Senior VP, General Counsel & Corporate Secretary | — |
| Ms. Miriam C. Provost Ph.D. | Vice President of Global Regulatory Affairs | 1961 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 67.00
- MACD 12/26/9
- 2.34
- EMA 9 of MACD
- -0.94
- MACD histogram
- 3.28
- SMA 50
- $80.04
- Price above SMA 50
- EMA 50
- $78.92
- Price above EMA 50
- SMA 200
- $92.11
- Price below SMA 200
- EMA 200
- $95.03
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
6 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $85.00
- Average
- $107.17
- High
- $120.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -14.3 | -15.0 | ||||||||||
| 2022 | -22.0 | +17.6 | +47.3 | -23.8 | +32.6 | +11.8 | +26.3 | +25.1 | -19.6 | +14.2 | +28.1 | -0.1 |
| 2023 | +10.3 | +22.5 | -6.9 | +5.2 | -6.7 | +16.3 | +12.8 | -30.1 | -20.8 | -29.0 | +98.9 | +5.7 |
| 2024 | +11.7 | -7.8 | -10.6 | +28.2 | +16.0 | +12.7 | -5.3 | +10.9 | -1.5 | -43.4 | +5.2 | -26.8 |
| 2025 | +1.6 | +11.0 | -3.0 | +34.8 | +40.5 | +8.1 | -8.6 | -4.6 | +0.6 | +14.5 | +17.3 | -19.1 |
| 2026 | +9.2 | +8.4 | -32.4 | +0.4 | -32.8 | -1.6 | +12.8 | +4.1 | +1.5 | -16.1 | +36.4 |
